Ophthalmological pharmacology has historically lacked systematic understanding of disease mechanisms, especially of those for the back of the eye. This is now changing with the discovery of novel targets and pathways paired with a greater understanding of the role of genetics in ocular pathologies.
The third annual Targeting Ocular Disorders will cover some of the most promising emerging therapies in the treatment of ocular diseases. Special focus with be given to age-related macular degeneration and retinopathy. Designated sessions will emphasize of the role of precise imaging techniques and animal models in accelerating preclinical development. Recent solutions in drug delivery to the back of the eye will also be discussed.
New Horizons for Glaucoma Therapy
Naj Sharif, Ph.D., Director, Pharmacology & Imaging; Global Regulatory Affairs, Alcon, a Novartis Company
Nitric Oxide-cGMP Signaling as a Therapeutic Target for Glaucoma
Emmanuel Buys, Ph.D., Assistant Professor, Anesthesia, Harvard Medical School; Associate Scientist, Broad Institute of MIT and Harvard
Interleukin-1 Receptor Antagonist Drug for Treatment of Inflammatory Diseases
Eric Furfine, Ph.D., CSO, Eleven Biotherapeutics
Characterization of a CrossMAb Antibody Targeting VEGF and Ang2 for Neovascular Diseases of the Eye
Guido Hartmann, Ph.D., Senior Principal Scientist, Neurology, Ophthalmology and Rare Disease DTA; Laboratory Head, Research and Early Development, F. Hoffmann-La Roche
Nuclear Receptors as Therapeutic Targets for Age-Related Macular Degeneration
Goldis Malek, Ph.D., Associate Professor, Ophthalmology, Duke University School of Medicine
Topical, Beta-Adrenergic Agonist as Novel Approach to Treat Diabetic Macular Edema and Retinopathy (DMER)
Robert Ferry, Ph.D., Professor, Pediatrics, University of Tennessee Health Science Center
Panel Discussion: Dry AMD under Attack
Moderator: David Sherris, Ph.D., CSO, RestorGenex, Inc.
Elias Reichel, M.D., Professor, Ophthalmology, Tufts University School of Medicine; Co-Founder, Hemera Biosciences, Inc.
Utility of in vivo Confocal Microscopy-Based Imaging Endpoints for the Assessment of Ocular Surface Inflammation
Pedram Hamrah, M.D., Assistant Professor, Ophthalmology, Harvard Medical School; Director, Ocular Surface Imaging Center, Massachusetts Eye and Ear Infirmary
Using OCT as a Biomarker in Disease
Jay S. Duker, M.D., Professor and Chair, Ophthalmology, Tufts University School of Medicine; Director, New England Eye Center
Challenges and Advances in Macromolecular Delivery to the Back of the Eye
Cindy Wu, Ph.D., Principal Scientist, Pharmaceutical Sciences, Allergan, Inc.
Long Acting Delivery of Antibody Therapeutics to the Back of the Eye
Robert Kelley, Ph.D., Senior Scientist, Drug Delivery, Genentech, Inc.
Talk Title to be Announced
Donald Jeffrey Zack, M.D., Professor, Genetic Engineering & Molecular Ophthalmology; Professor, Ophthalmology; Professor, Neuroscience, Johns Hopkins Medicine
Targeting the Inflammasome Signaling in a Mouse Model of Geographic Atrophy: A Gene Therapy Approach
Cristhian J. Ildefonso, Ph.D., Senior Postdoctoral Associate, Laboratory of Dr. Alfred S. Lewin, Molecular Genetics & Microbiology, University of Florida College of Medicine
For questions or suggestions about the meeting, please contact:
Associate Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-1346
For partnering and sponsorship information, please contact:
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483